News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Legal: Going to Court

October 1, 2006
Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-01-2006
Volume 0
Issue 0

In cases that reached a verdict between 2002 and 2006, the branded pharma industry won six of six cases by verdict in Delaware, but lost six of eight in New Jersey, all by summary judgement. Despite what judges say, it's no coincidence.

So the patent on one of your company's top-selling drugs has been challenged. If this is your first go-round with patent litigation, you're probably hearing horror stories about the cost and unpredictability of litigation. If you are a repeat player, then you may wonder if this next foray into court will turn into a quixotic journey to rival the last one. Either way, you are in for a stomach-churning ride. Much of what happens will be out of your immediate control.

Jonathan Singer

But there is one important thing that you can choose: where to litigate the case. Absent jurisdictional concerns—a real problem in some cases—you can generally file your patent lawsuit wherever you like. Your choice can affect the outcome of your case. You may rue or celebrate it when the verdict comes in.

So, what should you do? Your lawyers will tell you tales about this judge and that one. They can speak with seeming authority about the types of patents that hold up (or get knocked down) in pharmaceutical cases. You will probably just stare back at them and wonder whether they know what they're talking about. I know. I've been on the receiving end of those stares.

What your lawyers forget: You are a data person. You want to know what actually happens in these different venues. You want to see trends in the reported verdicts. You wouldn't make an important decision about a new product without the best information available. So why make a critical decision about where to file a lawsuit without hard data? No good reason. But more often than not, that's what happens.

No more. We examined cases available online that reached a judgment or verdict from 2002 to 2006 in three of the most popular venues for generic drug litigation—the Northern District of Illinois, the Southern District of New York, and the District of New Jersey—as well as the District of Delaware, which has more recently become popular. Is there one place that offers a discernable advantage to patent holders? Another that favors generic applicants? Or is this all nonsense, since each fact-intensive case is unique?

Trial results in light orange boxes Summary judgment results in dark orange boxes

It turns out that the District of Delaware stands out as the best place for branded drug manufacturers to litigate (see table).

Over the five years studied, six generic drug cases have reached a verdict in Delaware—all in favor of branded manufacturers. And while our sample size may be too small to draw firm conclusions, there were no reported summary judgments in favor of generics in Delaware from 2002 to 2006.

These data surprise even hardcore patent junkies. A landmark study of patent litigation, by Federal Circuit Judge Kimberly Moore, suggested that Delaware was actually worse than average for patentees, which may be true. But when it comes to pharmaceutical cases, Delaware appears to be the host with the most. Of course, it's possible that only strong cases were brought in Delaware, where the trial calendar is quick and the judicial willingness to try cases is high. Nonetheless, it seems clear that if you are a patentee with a good case, you will get a fair shake in Delaware. And that is saying a lot.

Consider the flipside. Where are the venues that give branded manufacturers consistent problems? Hello New Jersey and Illinois. Over the past five years, courts have granted summary judgment to generic drug makers in six cases in New Jersey and four in Illinois. Two verdicts in Illinois also went in favor of generic manufacturers. If you are a branded manufacturer and have an option, these are two jurisdictions to avoid.

One final point. If possible, don't file your case in a forum that has not seen significant drug litigation. If you think you're going to get a home-court advantage by litigating in your backyard, even if your backyard normally has lots of patent litigation, forget it. As the table demonstrates, filing in a court that does not see much drug litigation is a recipe for defeat.

Of course, there is no magic formula for choosing where to litigate. The intuition of a great lawyer can trump almost any data set. But as Mark Twain once said, "Get your facts first. Then you can distort them as you please."

Sidebar Headline Is associate vice president of leadership and management development at Sanofi Aventis. As president of the Society of Phamaceutical and Biotech Trainers (SPBT), he also serves on the editorial advisory board of Pharmaceutical Representative magazine lication). Prior to joininers (SPBT), he also Advanstar publication). Prior to joininers (SPBT), he also serves on the editorial advisory serves on the editorial advisory board of Pharmaceutical Representative magazine (an Advanstar publication). Prior to joininers (SPB, he also serves on the editorial advisory serves on the editorial advisory board of Pharmaceutical Representative magazine (an Advanstar publicarial advisory board of Pharmaceutical Representative magazine (an Advanstar publication). Prior to joininers (SPBT), he also serves on the editorial advisory board of Pharmaceutical Representative magazine (an Advanstar publication). Prior to joininers (SPBT), he also serves on the editorial advisory board of Pharmaceutical Representative magazine (an Advanstar publication). Prior to joining Aventis, Rauschkolb was the senior director of the University of Pfizer, Hospital and Specialty Representative Training.

Jonathan Singer is a principal in the Minneapolis office of Fish & Richardson. He can be reached at singer@fr.com

Articles in this issue

i3-378063-1408682021780.gif
A Survey of Medical Science Liaisons
i1-378061-1408682030435.jpg
Leadership: To Do: Take a Vacation
Back Page: Pharma's Mega-Brands
Back Page: Pharma's Mega-Brands
Marketing to Professionals: Key Opinion Control
Marketing to Professionals: Key Opinion Control
Direct to Consumer: If These Walls Had Ears
Direct to Consumer: If These Walls Had Ears
From the Editor: In Conflict
From the Editor: In Conflict
Alternative Media: Pharma Online: Not Just Black and White
Alternative Media: Pharma Online: Not Just Black and White
i3-378066-1408682013367.gif
Pharm Exec Q&A: Inside View
Sales and Marketing: Where the Buck Stops
Sales and Marketing: Where the Buck Stops
Smaller is Better
China: Big Rewards. Bigger Risks?
China: Big Rewards. Bigger Risks?
Born Again
Born Again
i1-378059-1408682036947.jpg
Washington Report: After Plan B: Out of the Quagmire, into the Data
i1-378058-1408682040257.jpg
Legal: Going to Court
"I Pray for the Welfare of Your Company..."
"I Pray for the Welfare of Your Company..."
Recent Videos
Marcel Botha, 10XBeta
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Marcel Botha, 10XBeta
Gameto - Addressing Regulatory Hurdles in iPSC-Based Fertility
Related Content

© JHVEPhoto - ©  JHVEPhoto - stock.adobe.com

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research

Andy Studna
May 21st 2025
Article

In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.


Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.


FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

Don Tracy, Associate Editor
May 20th 2025
Article

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.


Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.


FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

Don Tracy, Associate Editor
May 15th 2025
Article

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.


FDA Grants Accelerated Approval to AbbVie’s Emrelis for Previously Treated, Locally Advanced or Metastatic Non-Squamous NSCLC

FDA Grants Accelerated Approval to AbbVie’s Emrelis for Previously Treated, Locally Advanced or Metastatic Non-Squamous NSCLC

Don Tracy, Associate Editor
May 15th 2025
Article

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

Related Content

© JHVEPhoto - ©  JHVEPhoto - stock.adobe.com

FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research

Andy Studna
May 21st 2025
Article

In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.


Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.


FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

Don Tracy, Associate Editor
May 20th 2025
Article

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.


Navigating Distrust: Pharma in the Age of Social Media

Navigating Distrust: Pharma in the Age of Social Media

Miranda Schmalfuhs
February 18th 2025
Podcast

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.


FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

FDA Approves Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma

Don Tracy, Associate Editor
May 15th 2025
Article

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.


FDA Grants Accelerated Approval to AbbVie’s Emrelis for Previously Treated, Locally Advanced or Metastatic Non-Squamous NSCLC

FDA Grants Accelerated Approval to AbbVie’s Emrelis for Previously Treated, Locally Advanced or Metastatic Non-Squamous NSCLC

Don Tracy, Associate Editor
May 15th 2025
Article

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.